73422-88-5

Basic information

• Product Name: 1-phenylmethyl-3-methoxy-1,2-propanediol
• CAS NO: 73422-88-5
• Molecular Weight: 196.246
• Mol File: 73422-88-5.mol
• Article Data: 14

Chemical Properties

• CAS DataBase Reference: 1-phenylmethyl-3-methoxy-1,2-propanediol(CAS DataBase Reference)
• NIST Chemistry Reference: 1-phenylmethyl-3-methoxy-1,2-propanediol(73422-88-5)
• EPA Substance Registry System: 1-phenylmethyl-3-methoxy-1,2-propanediol(73422-88-5)

Safety Data

• Hazardous Substances Data: 73422-88-5(Hazardous Substances Data)

Upstream product

• 67-56-1 methanol 
• 2930-05-4 Benzyloxymethyl-oxiran 
• 124-41-4 sodium methylate 
• 1634-04-4 tert-butyl methyl ether 
• 64491-70-9 R(-)-glycidyl methyl ether 
• 100-51-6 benzyl alcohol 
• 100-52-7 benzaldehyde 
• 100-39-0 benzyl bromide 
• 90904-26-0 4-(1-methoxymethyl)-2-phenyl-1,3-dioxolane 
• 623-39-2 glycerol 1-monomethyl ether 
• 620-05-3 iodomethylbenzene 
• 13991-52-1 1-chloro-2-hydroxy-3-phenylmethoxypropane 

Downstream Products

• 153904-89-3 Butyric acid 2-benzyloxy-1-methoxymethyl-ethyl ester 
• 1407520-46-0 C₁₃H₂₁NO₂ 
• 103025-00-9 N-[9-(2-Benzyloxy-1-methoxymethyl-ethoxymethyl)-6-oxo-6,9-dihydro-1H-purin-2-yl]-acetamide 
• 103025-04-3 N-[7-(2-Benzyloxy-1-methoxymethyl-ethoxymethyl)-6-oxo-6,7-dihydro-1H-purin-2-yl]-acetamide 
• 264890-73-5 6-benzyloxy-5-hydroxy-5-methoxymethyl-3-hexynyl tert-butyldiphenylsilyl ether 
• 157372-75-3 1-(benzyloxy)-3-methoxypropan-2-one 

Relevant articles and documents

HETEROCYCLIC COMPOUNDS AS DIHYDROOROTATE DEHYDROGENASE INHIBITORS

Disclosed are compounds, compositions and methods for treating diseases, disorders, or medical conditions that are affected by the modulation of DHODH. Embodiments of such compounds are represented by Formula (I) and Formula (II) as follows: and wherein R1, R2, R3, R4, R5, R6, R7, R8, X1, X2, X3, X4, Y and Z, are defined herein.

COMPOUNDS FOR INHIBITING CELL PROLIFERATION IN EGFR-DRIVEN CANCERS

The invention features compounds, pharmaceutical compositions and methods for treating patients who have an EGFR-driven cancer of Formula (I), wherein the variables are as defined herein.

COMPOUNDS FOR INHIBITING CELL PROLIFERATION IN EGFR-DRIVEN CANCERS

The invention features compounds, pharmaceutical compositions and methods for treating patients who have an EGFR-driven cancer of formula (I), wherein the variables are as defined herein.